230 related articles for article (PubMed ID: 15711581)
1. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
2. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
[TBL] [Abstract][Full Text] [Related]
3. Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome.
Hegele RA
Mol Genet Metab; 2000 Dec; 71(4):539-44. PubMed ID: 11136544
[TBL] [Abstract][Full Text] [Related]
4. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
6. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
[TBL] [Abstract][Full Text] [Related]
7. Phenomics, lipodystrophy, and the metabolic syndrome.
Hegele RA
Trends Cardiovasc Med; 2004 May; 14(4):133-7. PubMed ID: 15177263
[TBL] [Abstract][Full Text] [Related]
8. A-type lamin-linked lipodystrophies.
Vigouroux C; Capeau J
Novartis Found Symp; 2005; 264():166-77; discussion 177-82, 227-30. PubMed ID: 15773753
[TBL] [Abstract][Full Text] [Related]
9. Lack of mutations in LMNA, its promoter region, and the cellular retinoic acid binding protein II (CRABP II) in HIV associated lipodystrophy.
Behrens GM; Genschel J; Schmidt RE; Schmidt HH
Eur J Med Res; 2003 May; 8(5):221-5. PubMed ID: 12844477
[TBL] [Abstract][Full Text] [Related]
10. Impact of genetic variation of PPARgamma in humans.
Meirhaeghe A; Amouyel P
Mol Genet Metab; 2004; 83(1-2):93-102. PubMed ID: 15464424
[TBL] [Abstract][Full Text] [Related]
11. Clinical, endocrine and metabolic studies in the kindred of familial partial lipodystrophy--a syndrome of insulin resistance.
Vaidya RA; Vaidya AD; Talwalkar SC; Mehtalia SD; Shringi MS; Pandey SN; Shah SJ; Godse C; Joshi JV; Sheth J; Kamdar VV
J Assoc Physicians India; 2002 Jun; 50():773-6. PubMed ID: 12240840
[TBL] [Abstract][Full Text] [Related]
12. Pushing the envelope on lipodystrophy.
Flier JS
Nat Genet; 2000 Feb; 24(2):103-4. PubMed ID: 10655047
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A/C R482W mutation.
Araújo-Vilar D; Loidi L; Domínguez F; Cabezas-Cerrato J
Horm Metab Res; 2003 Jan; 35(1):29-35. PubMed ID: 12669268
[TBL] [Abstract][Full Text] [Related]
14. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy.
Lüdtke A; Genschel J; Brabant G; Bauditz J; Taupitz M; Koch M; Wermke W; Worman HJ; Schmidt HH
Am J Gastroenterol; 2005 Oct; 100(10):2218-24. PubMed ID: 16181372
[TBL] [Abstract][Full Text] [Related]
15. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy.
Al-Shali K; Cao H; Knoers N; Hermus AR; Tack CJ; Hegele RA
J Clin Endocrinol Metab; 2004 Nov; 89(11):5655-60. PubMed ID: 15531525
[TBL] [Abstract][Full Text] [Related]
16. [Primary lipodystrophies].
Capeau J; Magré J; Lascols O; Caron M; Béréziat V; Vigouroux C
Ann Endocrinol (Paris); 2007 Feb; 68(1):10-20. PubMed ID: 17320032
[TBL] [Abstract][Full Text] [Related]
17. LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration.
Hegele RA; Cao H; Huff MW; Anderson CM
J Clin Endocrinol Metab; 2000 Sep; 85(9):3089-93. PubMed ID: 10999791
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
[TBL] [Abstract][Full Text] [Related]
19. [Lipodystrophic syndromes: congenital or acquired diseases of adipose tissue].
Capeau J; Vigouroux C; Magré J; Lascols O; Caron M; Bastard JP
C R Biol; 2006 Aug; 329(8):639-52; discussion 653-5. PubMed ID: 16860281
[TBL] [Abstract][Full Text] [Related]
20. Single-nucleotide polymorphisms of the nuclear lamina proteome.
Hegele RA; Yuen J; Cao H
J Hum Genet; 2001; 46(6):351-4. PubMed ID: 11393540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
